MX2024005453A - Composiciones y tratamientos con nirogacestat. - Google Patents

Composiciones y tratamientos con nirogacestat.

Info

Publication number
MX2024005453A
MX2024005453A MX2024005453A MX2024005453A MX2024005453A MX 2024005453 A MX2024005453 A MX 2024005453A MX 2024005453 A MX2024005453 A MX 2024005453A MX 2024005453 A MX2024005453 A MX 2024005453A MX 2024005453 A MX2024005453 A MX 2024005453A
Authority
MX
Mexico
Prior art keywords
nirogacestat
compositions
treatments
treatment
methods
Prior art date
Application number
MX2024005453A
Other languages
English (en)
Inventor
Shinta Cheng
Todd Webster Shearer
Kristin Patterson
Rex Williams
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of MX2024005453A publication Critical patent/MX2024005453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente divulgación se refiere a composiciones y métodos de tratamiento que comprenden nirogacestat o una sal farmacéuticamente aceptable de este.
MX2024005453A 2021-11-05 2022-11-04 Composiciones y tratamientos con nirogacestat. MX2024005453A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263635P 2021-11-05 2021-11-05
US202263365125P 2022-05-20 2022-05-20
US202263365193P 2022-05-23 2022-05-23
US202263369733P 2022-07-28 2022-07-28
PCT/US2022/079309 WO2023081830A2 (en) 2021-11-05 2022-11-04 Compositions and treatments with nirogacestat

Publications (1)

Publication Number Publication Date
MX2024005453A true MX2024005453A (es) 2024-07-22

Family

ID=86242233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005453A MX2024005453A (es) 2021-11-05 2022-11-04 Composiciones y tratamientos con nirogacestat.

Country Status (9)

Country Link
US (1) US20240316007A1 (es)
EP (1) EP4426294A2 (es)
KR (1) KR20240104138A (es)
AU (1) AU2022380837A1 (es)
CA (1) CA3237521A1 (es)
CO (1) CO2024006819A2 (es)
IL (1) IL312541A (es)
MX (1) MX2024005453A (es)
WO (1) WO2023081830A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
US20230372301A1 (en) 2022-05-20 2023-11-23 Springworks Therapeutics, Inc. Treatments with nirogacestat

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015092614A1 (en) * 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
US10590087B1 (en) * 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
US20230112444A1 (en) * 2020-01-16 2023-04-13 Springworks Therapeutics, Inc. Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors
BR112022018987A2 (pt) * 2020-03-26 2022-11-01 Seagen Inc Métodos de tratamento de mieloma múltiplo

Also Published As

Publication number Publication date
CO2024006819A2 (es) 2024-06-07
WO2023081830A3 (en) 2023-06-08
KR20240104138A (ko) 2024-07-04
IL312541A (en) 2024-07-01
EP4426294A2 (en) 2024-09-11
CA3237521A1 (en) 2023-05-11
US20240316007A1 (en) 2024-09-26
AU2022380837A1 (en) 2024-06-06
WO2023081830A2 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
MX2024005453A (es) Composiciones y tratamientos con nirogacestat.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
NZ761388A (en) Methods of treatment for cystic fibrosis
CR20220082A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
EA030735B9 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
MX2018009173A (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2022000845A (es) Compuestos inhibidores.
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
PH12019501245A1 (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
ZA202212095B (en) Il4i1 inhibitors and methods of use
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.